Versor Investments LP Sells 30,587 Shares of Axonics, Inc. (NASDAQ:AXNX)

Versor Investments LP lessened its stake in shares of Axonics, Inc. (NASDAQ:AXNX - Free Report) by 46.2% in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 35,615 shares of the company's stock after selling 30,587 shares during the period. Axonics accounts for approximately 0.4% of Versor Investments LP's holdings, making the stock its 28th biggest position. Versor Investments LP owned 0.07% of Axonics worth $2,479,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Headlands Technologies LLC lifted its position in shares of Axonics by 31.1% in the first quarter. Headlands Technologies LLC now owns 1,117 shares of the company's stock worth $77,000 after buying an additional 265 shares in the last quarter. Xponance Inc. boosted its position in shares of Axonics by 7.5% during the 2nd quarter. Xponance Inc. now owns 3,231 shares of the company's stock valued at $217,000 after acquiring an additional 225 shares during the last quarter. Janney Montgomery Scott LLC purchased a new position in shares of Axonics in the first quarter valued at $218,000. Mercer Global Advisors Inc. ADV grew its holdings in shares of Axonics by 12.7% in the second quarter. Mercer Global Advisors Inc. ADV now owns 6,981 shares of the company's stock valued at $469,000 after purchasing an additional 785 shares in the last quarter. Finally, SG Americas Securities LLC increased its position in Axonics by 379.6% in the second quarter. SG Americas Securities LLC now owns 8,321 shares of the company's stock worth $559,000 after purchasing an additional 6,586 shares during the last quarter. Institutional investors own 99.48% of the company's stock.

Wall Street Analysts Forecast Growth

Separately, Needham & Company LLC reissued a "hold" rating on shares of Axonics in a research note on Friday. Eight research analysts have rated the stock with a hold rating, According to MarketBeat.com, the stock currently has an average rating of "Hold" and an average target price of $71.00.

Insider Buying and Selling

In related news, CFO Kari Leigh Keese sold 2,961 shares of the firm's stock in a transaction that occurred on Wednesday, October 2nd. The stock was sold at an average price of $69.41, for a total transaction of $205,523.01. Following the completion of the sale, the chief financial officer now directly owns 40,362 shares of the company's stock, valued at approximately $2,801,526.42. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 1.85% of the stock is owned by corporate insiders.

Axonics Stock Up 0.1 %

NASDAQ AXNX traded up $0.06 on Monday, hitting $70.48. 501,626 shares of the stock were exchanged, compared to its average volume of 701,118. Axonics, Inc. has a 52-week low of $50.55 and a 52-week high of $70.75. The stock has a fifty day moving average price of $69.70 and a two-hundred day moving average price of $68.46.

Axonics Company Profile

Axonics, Inc, a medical technology company, engages in the development and commercialization of novel products for the treatment of bladder and bowel dysfunction. Its sacral neuromodulation (SNM) systems are used to treat patients with overactive bladder (OAB), including urinary urge incontinence and urinary urgency frequency, as well as fecal incontinence (FI) and non-obstructive urinary retention (UR); and rechargeable (R20) and recharge-free (F15) implantable SNM systems that delivers mild electrical pulses to the targeted sacral nerve to restore normal communication to and from the brain to reduce the symptoms of OAB, UR, and FI.